The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous X None **Names**

Entity Type

0001261249

Name of Issuer

X Corporation

Limited Partnership

AGILE THERAPEUTICS INC Limited Liability Company Jurisdiction of General Partnership

Incorporation/Organization Business Trust DELAWARE Other (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

AGILE THERAPEUTICS INC

Street Address 1 Street Address 2

366 WALL STREET

State/Province/Country ZIP/PostalCode **Phone Number of Issuer** City

PRINCETON 08540-1715 609-940-0300 NJ

3. Related Persons

Last Name First Name Middle Name

Rossi **Thomas** M.

> **Street Address 1 Street Address 2**

c/o Agile Therapeutics, Inc. 366 Wall Street

> State/Province/Country ZIP/PostalCode City

NJ 08540-1715 Princeton

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Altomari Al

> **Street Address 1** Street Address 2

8 Yeger Drive

City State/Province/Country ZIP/PostalCode

NJ Lawrenceville 08648

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Hong Karen

> **Street Address 1 Street Address 2**

c/o ProQuest Investments 90 Nassau Street, 5th Floor State/Province/Country ZIP/PostalCode City

Princeton NJ 08542

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name Middle Name First Name

Tsang Joyce

Street Address 1 Street Address 2 c/o ProQuest Investments 90 Nassau Street, 5th Floor

> City State/Province/Country ZIP/PostalCode

Princeton NJ 08542

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Miller Dean

> **Street Address 1** Street Address 2

c/o Novitas Capital 1200 Liberty Ridge Drive, Suite 310

> State/Province/Country ZIP/PostalCode City

PA 19087 Wayne

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Health Care Agriculture Retailing

Banking & Financial Services Biotechnology Restaurants Commercial Banking Health Insurance Technology

Insurance Hospitals & Physicians Computers Investing

X Pharmaceuticals Telecommunications **Investment Banking**

Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under Real Estate Airlines & Airports the Investment Company

Commercial Act of 1940? **Lodging & Conventions** Construction Yes No

Tourism & Travel Services Other Banking & Financial Services **REITS & Finance**

Other Travel **Business Services**

Residential Other Energy

Other Real Estate Coal Mining

Environmental Services

Energy Conservation

Oil & Gas

Other Energy

Electric Utilities

Revenue Range	OR	Aggregate Net Asset Value Range					
X No Revenues		No Aggregate No					
\$1 - \$1,000,000		\$1 - \$5,000,000					
\$1,000,001 - \$5,000,000 \$5,000,001 -		\$5,000,001 - \$25					
\$25,000,000		\$25,000,001 - \$5	0,000,000				
\$25,000,001 - \$100,000,000		\$50,000,001 - \$1	00,000,000				
Over \$100,000,000		Over \$100,000,0					
Decline to Disclose		Decline to Disclo	ose				
Not Applicable		Not Applicable					
6. Federal Exemption(s) and Ex	clusion(s) Claim	ed (select all that a	apply)				
Rule 504(b)(1) (not (i), (ii) or (iii))		Rule 505					
Rule 504 (b)(1)(i)		X Rule 506					
Rule 504 (b)(1)(ii)							
Rule 504 (b)(1)(iii)				et Section 3(c)			
		Section 3(c)(1)	Section 3(c)(9)			
		Section 3(c)(2)	Section 3(c)(10)			
		Section 3(c)(3)	Section 3(c)(11)			
		Section 3(c)(4)	Section 3(c)(12)			
		Section 3(c)(5)	Section 3(c)(13)			
		Section 3(c)(6)	Section 3(c)(14)			
		Section 3(c)(7	7)				
7. Type of Filing							
X New Notice Date of First S. Amendment	ale 2009-12-30	First Sale Yet to	Occur				
8. Duration of Offering							
Does the Issuer intend this offering to last more than one year? Yes X No							
9. Type(s) of Securities Offered	(select all that a	pply)					
X Equity Pooled Investment Fund Inter							
Debt		Tenant-in-Common Securities					
X Option, Warrant or Other Right to Acquire Another Se			Mineral P	roperty Securities			
X Security to be Acquired Upon Exercise of Opt Other Right to Acquire Security		tion, Warrant or	Other (describe)				
10. Business Combination Tran	saction						
Is this offering being made in case a merger, acquisition or exchange		business combina	tion transac	tion, such as Yes X No			
Clarification of Response (if Ne	ecessary):						
11. Minimum Investment	J /						
11. Minimum III Conneil							

Recipient

12. Sales Compensation

Minimum investment accepted from any outside investor \$0 USD

(Associated) Broker or Dealer X None

(Associated) Broker or Dealer CRD Number X None

Street Address 1

Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply) Check "All States" or check individual States

All States Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$2,000,000 USD or Indefinite

Total Amount Sold \$1,010,822 USD

Total Remaining to be Sold \$989,178 USD or Indefinite

Clarification of Response (if Necessary):

Offering amount does not include exercise price for warrants issued in financing (\$1,800,055.20) or principal and interest under notes converted into shares (\$1,028,088.43).

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:



15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$90,000 USD X Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment

Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
AGILE THERAPEUTICS INC	/s/ Thomas M. Rossi	Thomas M. Rossi	President and Chief Executive Officer	2010-01-12

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.